Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib

BACKGROUND: Lapatinib is a tyrosine kinase inhibitor that blocks the HER2 receptor and is typically used in the setting of metastatic breast cancer. Both ERBB2 (HER2) and ERBB3 (HER3) belong to the same family of receptor tyrosine kinases. Dimerization of these receptors leads to activation of cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Strickley, John D., Spalding, Aaron C., Haeberle, M. Tye, Brown, Timothy, Stevens, Don A., Jung, Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114032/
https://www.ncbi.nlm.nih.gov/pubmed/30181930
http://dx.doi.org/10.1186/s40164-018-0111-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114032/
https://www.ncbi.nlm.nih.gov/pubmed/30181930
http://dx.doi.org/10.1186/s40164-018-0111-z

Ejemplares similares